Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-13 2:14 pm Purchase |
2024-12-31 | 13G | BioMarin Pharmaceutical Inc. BMRN |
Capital Research Global Investors | 12,991,772 6.800% |
2,217,131 (+20.58%) |
Filing History |
| 2024-09-30 4:29 pm Purchase |
2024-09-20 | 13G | BioMarin Pharmaceutical Inc. BMRN |
VIKING GLOBAL INVESTORS LP | 9,753,293 5.100% |
9,753,293 (New Position) |
Filing History |
| 2024-07-10 1:14 pm Purchase |
2024-06-28 | 13G | BioMarin Pharmaceutical Inc. BMRN |
The Vanguard Group | 18,992,533 10.000% |
943,976 (+5.23%) |
Filing History |
| 2024-07-08 4:32 pm Purchase |
2024-06-30 | 13G | BioMarin Pharmaceutical Inc. BMRN |
BlackRock Inc. BLK |
22,779,744 12.000% |
8,038,908 (+54.53%) |
Filing History |
| 2024-02-13 5:01 pm Purchase |
2023-12-29 | 13G | BioMarin Pharmaceutical Inc. BMRN |
The Vanguard Group | 18,048,557 9.580% |
683,477 (+3.94%) |
Filing History |
| 2024-02-13 1:21 pm Sale |
2023-12-31 | 13G | BioMarin Pharmaceutical Inc. BMRN |
Dodge & Cox | 13,994,063 7.400% |
-389,600 (-2.71%) |
Filing History |
| 2024-02-12 4:01 pm Purchase |
2023-12-31 | 13G | BioMarin Pharmaceutical Inc. BMRN |
PRIMECAP MANAGEMENT CO/CA/ | 18,414,374 9.780% |
833,515 (+4.74%) |
Filing History |
| 2024-02-09 5:46 pm Purchase |
2024-02-07 | 13G | BioMarin Pharmaceutical Inc. BMRN |
Capital Research Global Investors | 10,774,641 5.700% |
5,123,640 (+90.67%) |
Filing History |
| 2024-01-26 11:49 am Sale |
2023-12-31 | 13G | BioMarin Pharmaceutical Inc. BMRN |
BlackRock Inc. BLK |
14,740,836 7.800% |
-465,854 (-3.06%) |
Filing History |
| 2023-02-14 1:25 pm Sale |
2022-12-31 | 13G | BioMarin Pharmaceutical Inc. BMRN |
Dodge & Cox | 14,383,663 7.700% |
-441,386 (-2.98%) |
Filing History |
| 2023-02-13 3:32 pm Sale |
2023-02-14 | 13G | BioMarin Pharmaceutical Inc. BMRN |
Capital Research Global Investors | 5,651,001 3.000% |
-7,021,007 (-55.41%) |
Filing History |
| 2023-02-09 4:01 pm Sale |
2022-12-31 | 13G | BioMarin Pharmaceutical Inc. BMRN |
PRIMECAP MANAGEMENT CO/CA/ | 17,580,859 9.460% |
-223,921 (-1.26%) |
Filing History |
| 2023-02-09 11:12 am Purchase |
2022-12-30 | 13G | BioMarin Pharmaceutical Inc. BMRN |
The Vanguard Group | 17,365,080 9.340% |
1,014,049 (+6.20%) |
Filing History |
| 2023-02-03 4:27 pm Purchase |
2022-12-31 | 13G | BioMarin Pharmaceutical Inc. BMRN |
BlackRock Inc. BLK |
15,206,690 8.200% |
1,185,398 (+8.45%) |
Filing History |
| 2022-03-11 2:13 pm Unchanged |
2021-12-31 | 13G | BioMarin Pharmaceutical Inc. BMRN |
BlackRock Inc. BLK |
14,021,292 7.600% |
0 (Unchanged) |
Filing History |
| 2022-02-14 12:48 pm Purchase |
2021-12-31 | 13G | BioMarin Pharmaceutical Inc. BMRN |
Dodge & Cox | 14,825,049 8.100% |
5,028,125 (+51.32%) |
Filing History |
| 2022-02-10 12:21 pm Sale |
2021-12-31 | 13G | BioMarin Pharmaceutical Inc. BMRN |
PRIMECAP MANAGEMENT CO/CA/ | 17,804,780 9.700% |
-400,554 (-2.20%) |
Filing History |
| 2022-02-09 3:33 pm Sale |
2021-12-31 | 13G | BioMarin Pharmaceutical Inc. BMRN |
The Vanguard Group | 16,351,031 8.910% |
-18,658 (-0.11%) |
Filing History |
| 2022-02-08 5:05 pm Sale |
2021-12-31 | 13G | BioMarin Pharmaceutical Inc. BMRN |
BlackRock Inc. BLK |
14,021,292 7.600% |
-745,600 (-5.05%) |
Filing History |
| 2022-01-10 12:04 pm Sale |
2022-01-10 | 13G | BioMarin Pharmaceutical Inc. BMRN |
Capital Research Global Investors | 12,672,008 6.900% |
-9,521,519 (-42.90%) |
Filing History |